Girish Dayma

Girish Dayma

Auto-generated profile, based on publicly available information

Girish Dayma

Community Health Research Unit Pune Maharashtra 411020 KEM Hospital Research Centre

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SRShrish Raut
Shrish Raut
AAAditi Apte
Aditi Apte
MSManikandan Srinivasan
Manikandan Srinivasan
NDNonita Dudeja
Nonita Dudeja
GDGirish Dayma
Girish Dayma
ABAshish Bavdekar
Ashish Bavdekar
Background: Pregnancy and early infancy are considered to be the vulnerable phases for severe influenza infection causing morbidity and mortality. Despite WHO recommendations, influenza is not included in the immunization programs of many low- and middle-income countries. This systematic review is aimed at identifying barriers and facilitators for maternal influenza vaccination amongst the perinatal women and their health care providers in low- and middle-income countries. Methods: We selected 11 studies from the 1669 records identified from PubMed, CABI, EMBASE and Global Health databases. Studies related to both pandemic and routine influenza vaccination and studies conducted amongst women in the antenatal as well as postnatal period were included. Both qualitative, quantitative, cross-sectional and interventional studies were included. Results: Knowledge about influenza disease, perception of the disease severity during pregnancy and risk to the foetus/newborn and perceived benefits of influenza vaccination during pregnancy were associated with increased uptake of influenza vaccination during pregnancy. Recommendation by health care provider, vaccination in previous pregnancy and availability of vaccine in public health system facilitated vaccine uptake. High parity, higher education, vaccination in the later months of pregnancy, less than 4 antenatal visits, concerns about vaccine safety and negative publicity in media were identified as barriers for influenza vaccination. Lack of government recommendation, concerns about safety and effectiveness and distrust in manufacturer were the barriers for the healthcare providers to recommend vaccination. Conclusion: While availability of influenza vaccine in public health system can be a key to the success of vaccine implementation program, increasing the awareness about need and benefits of maternal influenza vaccination amongst pregnant women as well as their health care providers is crucial to improve the acceptance of maternal influenza vaccination in low and middle-income countries.

6 December 2024 in PLOS Digital Health
Verified
Journal Article
Open access
PDF file
PSParth Sharma
Parth Sharma
SRShirish Rao
Shirish Rao
PKPadmavathy Krishna Kumar
Padmavathy Krishna Kumar
ANAiswarya R. Nair
Aiswarya R. Nair
DADisha Agrawal
Disha Agrawal
VPVikram Patel
Vikram Patel
It is widely assumed that telehealth tools like mHealth (mobile health), telemedicine, and tele-education can supplement the efficiency of Healthcare Providers (HCPs). We conducted a systematic review of evidence on the barriers and facilitators associated with the use of telehealth by HCPs in India. A systematic literature search following a pre-registered protocol (https://doi.org/10.17605/OSF.IO/KQ3U9 [PROTOCOL DOI]) was conducted on PubMed. The search strategy, inclusion, and exclusion criteria were based on the World Health Organization’s action framework on Human Resources for Health (HRH) and Universal Health Coverage (UHC) in India with a specific focus on telehealth tools. Eligible articles published in English from 1st January 2001 to 17th February 2022 were included. One hundred and six studies were included in the review. Of these, 53 studies (50%) involved mHealth interventions, 25 (23.6%) involved telemedicine interventions whereas the remaining 28 (26.4%) involved the use of tele-education interventions by HCPs in India. In each category, most of the studies followed a quantitative study design and were mostly published in the last 5 years. The study sites were more commonly present in states in south India. The facilitators and barriers related to each type of intervention were analyzed under the following sub-headings- 1) Human resource related, 2) Application related 3) Technical, and 4) Others. The interventions were most commonly used for improving the management of mental health, non-communicable diseases, and maternal and child health. The use of telehealth has not been uniformly studied in India. The facilitators and barriers to telehealth use need to be kept in mind while designing the intervention. Future studies should focus on looking at region-specific, intervention-specific, and health cadre-specific barriers and facilitators for the use of telehealth.

27 February 2024 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
MAMangaiarkarasi S. Asokan
Mangaiarkarasi S. Asokan
RJRoshni Florina Joan
Roshni Florina Joan
SBSudhir Babji
Sudhir Babji
GDGirish Dayma
Girish Dayma
PNPrajitha Nadukkandy
Prajitha Nadukkandy
SMSatyajit Mayor
Satyajit Mayor
There are limited global data on head-to-head comparisons of vaccine platforms assessing both humoral and cellular immune responses, stratified by pre-vaccination serostatus. The COVID-19 vaccination drive for the Indian population in the age group 18–45 years began in April 2021 when seropositivity rates in the general population were rising due to the delta wave of COVID-19 pandemic during April–May 2021. Between June 30, 2021, and Jan 28, 2022, we enrolled 691 participants in the age group 18–45 years across four clinical sites in India. In this non-randomised and laboratory blinded study, participants received either two doses of Covaxin® (4 weeks apart) or two doses of Covishield™ (12 weeks apart) as per the national vaccination policy. The primary outcome was the seroconversion rate and the geometric mean titre (GMT) of antibodies against the SARS-CoV-2 spike and nucleocapsid proteins post two doses. The secondary outcome was the frequency of cellular immune responses pre- and post-vaccination. When compared to pre-vaccination baseline, both vaccines elicited statistically significant seroconversion and binding antibody levels in both seronegative and seropositive individuals. In the per-protocol cohort, Covishield™ elicited higher antibody responses than Covaxin® as measured by seroconversion rate (98.3% vs 74.4%, p < 0.0001 in seronegative individuals; 91.7% vs 66.9%, p < 0.0001 in seropositive individuals) as well as by anti-spike antibody levels against the ancestral strain (GMT 1272.1 vs 75.4 binding antibody units/ml [BAU/ml], p < 0.0001 in seronegative individuals; 2089.07 vs 585.7 BAU/ml, p < 0.0001 in seropositive individuals). As participants at all clinical sites were not recruited at the same time, site-specific immunogenicity was impacted by the timing of vaccination relative to the delta and omicron waves. Surrogate neutralising antibody responses against variants-of-concern including delta and omicron was higher in Covishield™ recipients than in Covaxin® recipients; and in seropositive than in seronegative individuals after both vaccination and asymptomatic infection (omicron variant). T cell responses are reported from only one of the four site cohorts where the vaccination schedule preceded the omicron wave. In seronegative individuals, Covishield™ elicited both CD4+ and CD8+ spike-specific cytokine-producing T cells whereas Covaxin® elicited mainly CD4+ spike-specific T cells. Neither vaccine showed significant post-vaccination expansion of spike-specific T cells in seropositive individuals. Covishield™ elicited immune responses of higher magnitude and breadth than Covaxin® in both seronegative individuals and seropositive individuals, across cohorts representing the pre-vaccination immune history of most of the vaccinated Indian population. Corporate social responsibility (CSR) funding from Hindustan Unilever Limited (HUL) and Unilever India Pvt. Ltd. (UIPL).

15 September 2023 in Journal of Global Health
Verified
Journal Article
Open access
DADhiraj Agarwal
Dhiraj Agarwal
MGManisha Gore
Manisha Gore
AKANAND SHANTARAM KAWADE
ANAND SHANTARAM KAWADE
SRSudipto Roy
Sudipto Roy
ABAshish Bavdekar
Ashish Bavdekar
RCRESPIRE Collaboration
RESPIRE Collaboration
Pneumonia is a major cause of under-five mortality worldwide, especially in India [1–3], where despite progress in reducing under-five mortality, pneumonia-related deaths remain a public health concern [4,5]. Integrated management of childhood illness (IMCI) is a recommended approach for managing childhood illnesses, including pneumonia, in low-resource settings [6]. However, the use of pulse oximeters (PO) […]

22 March 2024 in medRxiv
Verified
Preprint
Open access
PDF file
NMNisha Mutalikdesai
Nisha Mutalikdesai
KTKajal Tonde
Kajal Tonde
KSKanchan Shinde
Kanchan Shinde
RKRakesh Kumar
Rakesh Kumar
SGSurbhi Gupta
Surbhi Gupta
RPRutuja Patil
Rutuja Patil
Background: Integrating Tuberculosis (TB), Diabetes Mellitus (DM), and Tobacco-Control (TC) programs in India presents a promising strategy to address the triple burden of these diseases. However, limited information exists regarding the feasibility and influencing factors of such integration. This study investigates potential barriers and facilitators to integrate TB, DM, and TC programs in Ambegaon Block of Pune District in Maharashtra and Ballabgarh Block of Faridabad District in Haryana states of India. Methods: Qualitative in-depth interviews were conducted between Nov 2022 to March 2023 among health workers, program managers, and stakeholders involved in program implementation (n=32). Interview guide was based on World Health Organization’s Health System Strengthening framework. Purposive sampling and snowball sampling were used to select participants. Rapid analysis of the data was done using the WHO HSS Framework. Results: There were barriers and facilitators for the integration of TB-DM-TC programs observed in India. The primary challenges for integration are at the level of service delivery which is largely attributed to inadequate implementation of all three programs and negligible involvement of private practitioners in the program implementation. Moreover, inadequate referral system, insufficient infrastructure, limited resources, a shortage of trained staff, and lack of essential drugs and equipment impeded the uptake and coverage of services. Conclusion: The results highlight the critical importance of addressing barriers and facilitators of implementation program in India to build a robust structure of managing the triple burden of TB, DM and tobacco control. The proposed strategies, such as sensitizing health system staff, implementing feedback and referral systems, and developing cross-program digital platforms offer a roadmap for policymakers and healthcare system managers. A multidimensional approach is vital for overcoming barriers and facilitating integration.

23 December 2025 in Vaccine
Verified
Journal Article
Open access
VSVistasp Sethna
Vistasp Sethna
AAA. Apte
A. Apte
SSS. Sanghavi
S. Sanghavi
YTY. Tang
Y. Tang
CPC. Poonawalla
C. Poonawalla
ABA. Bavdekar
A. Bavdekar
Reduction in the vaccine serotype (VT) carriage is a surrogate marker of pneumococcal vaccines protection. PNEUMOSIL®, a 10-valent pneumococcal conjugate vaccine (PCV) has been recently introduced in the national immunization program of India in a 2 + 1 schedule. Owing to scarcity of data about impact of PNEUMOSIL® vaccination on VT-carriage, the current study was conducted in Indian children to assess its impact. This was a community-based cross-sectional observational study conducted between November 2022-March 2023 in rural areas of Pune, India. The study population included healthy children either fully vaccinated with PNEUMOSIL® 2 + 1 schedule through Universal Immunization Program or PCV-naïve. The vaccinated group was enrolled at least 4 months after receipt of the last PCV dose. Nasopharyngeal swabs were collected upon enrolment using World Health Organization methods in all children to isolate Streptococcus pneumoniae and identify serotypes using a Quellung test. The VT-carriage were compared between PCV-vaccinated and PCV-naïve using univariate and multivariate logistic regression. The study enrolled 700 healthy children; 350 children aged 15-20 months previously fully vaccinated with PNEUMOSIL® 2 + 1 schedule through UIP and 350 PCV-naïve children aged 16-21 months. Overall S. pneumoniae carriage in PCV-vaccinated and PCV-naïve groups was 63·1 % (95 % CI 57·9 %-68·2 %) and 66·3 % (95 % CI 61·1 %-71·2 %), respectively (p = 0·384). VT-carriage occurred in 23·4 % (95 % CI 19·1 %-28·2 %) of vaccinated children and 30·9 % (95 % CI 26·1 %-36·0 %) of PCV-naïve participants (24·3 % reduction, p = 0·027). After adjusting for colonization risk factors, PNEUMOSIL® vaccination was associated with 32 % reduction in odds of VT colonization compared with PCV-naïve participants [OR = 0·68; 95 % CI 0·49-0·96]. The observed reduction in VT-carriage amongst Indian children was comparable to that observed with other PCVs that have demonstrated marked declines in disease transmission. These results suggest PNEUMOSIL® could be an effective public health tool in decreasing pneumococcal disease.